Zimmer Biomet Holdings, Inc. ZBH NYSE

Zimmer Biomet Holdings, Inc. (ZBH) generated $517.3M in operating cash flow for quarter ending 2025-12-31. After capital expenditures of $151.4M, free cash flow was $668.7M.

Free cash flow margin was 29.8% of revenue. Cash conversion ratio was 3.71x, indicating earnings are backed by cash.

The company returned $47.5M in dividends and $250M in share buybacks to shareholders during the quarter.

Criteria supported by this page:

• HEALTH (67/100, Partial) — cash generation is adequate but may not fully cover debt in stressed conditions
• MOAT (65/100, Partial) — cash flow generation is present but not at levels indicating a wide moat
• INCOME (45/100) — Cash conversion ratio was 3.71x confirms earnings are backed by real cash flow

Overall SharesGrow Score: 63/100 with 2/7 criteria passed.